New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who take the same medications. One possible reason for the weight loss ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

GLP-1 drugs like semaglutide and tirzepatide show promise in treating obesity, with benefits including weight loss and improved metabolic health. However, concerns about long-term safety, cost, and ...

GLP-1 drugs show promise for obesity treatment but raise concerns about long-term use, access and sustainability. Learn more about the future of obesity care.

An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed.

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented ... “Federico II” gave the glucagon-like peptide-1 (GLP-1) ...

Pfizer's push into obesity will be led by a once-daily formulation of GLP-1 agonist danuglipron as it tries to catch up with Novo Nordisk and Eli Lilly.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

Several top nutrition and obesity organizations provided the first unified guidelines for helping patients manage their ...